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Background: Circulating FGF21 levels are commonly elevated in disease states. There is limited infor-
mation regarding concentrations of circulating FGF21 in the absence of disease, as well as age-related
differences in body composition that may contribute to FGF21 regulation across groups.
Objective: The objectives of this study were to assess FGF21 levels across age groups (childhood to elder
adulthood), and investigate whether body composition indices are associated with age-related differ-
ences in circulating FGF21.
Materials and methods: We cross-sectionally analyzed serum concentrations of FGF21 in 184 healthy
subjects aged 5e80 y (45% male). Multiple linear regression was performed to assess the independent
association of categorical age (children: 5e12 y, young adults: 20e29 y, adults: 30e50 y, older adults: 55
e64 y, elder adults: 65e80 y) with FGF21 concentration taking into account DXA-measured body
composition indices [bone mineral density (BMD) and percent lean, trunk, and fat mass]. We also
stratiﬁed analysis by tertile of FGF21.
Results: Incremental increases in FGF21 levels were observed across age groups (youngest to highest).
Age group was positively associated with FGF21 level independent of body composition indices (age
group variable: b ¼ 0.25, 0.24, 0.24, 0.23, all P < 0.0001, controlling for percent lean, BMD, percent fat,
and percent trunk fat, respectively). By FGF21 tertile, age group was associated with FGF21 in the lowest
tertile only (b ¼ 13.1, 0.19, 0.18, all P  0.01, accounting for percent lean, fat and trunk fat, respectively),
but not when accounting for BMD.
Conclusions: Our ﬁndings in a healthy population display an age-related increase in serum FGF21,
highlighting a potential age effect in response to metabolic demand over the lifecourse. FGF21 levels
increase with age independently of body composition. At lower levels of FGF21, BMD, but not other body
composition parameters, attenuates the association between FGF21 level and age, suggesting the
metabolic demand of the skeleton may provide a link between FGF21 and energy metabolism.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).; BMD, bone mineral density; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; ELISA, enzyme-linked
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Fibroblast growth factor 21 (FGF21) has garnered signiﬁcant
interest in recent years, given its emerging role in intermediary
metabolism involving glucose and lipid utilization. FGF21 is
released into the circulation from the liver, adipose tissue, and
skeletal muscle where it is involved in adaptations to energy de-
mand across tissues. FGF21 expression by the liver and adipose
tissue is largely controlled by peroxisome proliferator activated
receptor (PPAR) a and l, respectively [1,2], and in skeletal muscle by
the insulin/Akt pathway [1]. An insulin-signaling pathway-depen-
dent mechanism has been suggested to be the primary action in
skeletal muscle [1], and in adipose tissue, an insulin-independent
mechanism promotes glucose uptake by enhancing the expres-
sion of GLUT1 [3]. The metabolic effects of FGF21 in adipocytes are
also mediated by b-Klotho, a single-pass transmembrane protein
induced during adipogenesis [4]. FGF21 has been shown to improve
pancreatic b-cell function and survival by activation of extracellular
signal-regulated kinase 1/2 and Akt signaling pathways [5]. In the
liver, down-regulation of FGF21 leads to fatty liver, dyslipidemia,
and reduced serum ketones due to the altered expression of key
genes involved in hepatic lipid and ketone metabolism, potentially
linking FGF21 to metabolic disease [6]. Moreover, increased pro-
duction of FGF21 in transgenic mice has been associated with body
weight maintenance and longevity [7]. These ﬁndings in animal-
based studies suggest FGF21 is a potent metabolic regulator with
beneﬁcial independent effects on glucose, lipid and overall energy
metabolism. However, the extent to which metabolic regulation by
FGF21 is modiﬁed with aging has not been explored.
Changes in accumulation, degeneration and metabolic activity
of various body tissues, well-accepted as part of the aging process,
may affect synthesis and release of FGF21. Adipocytes have been
shown to be an important source of FGF21 production, whereas the
liver has been previously considered as the main source of FGF21 in
circulation [8]. More recently, skeletal muscle expression and
secretion of FGF21 have been shown to lead to a ﬁvefold increase in
circulating FGF21 concentration [9]. Because the aging process is
associated with reciprocal modiﬁcation of body composition e
adiposity increases, muscle mass decreases, in general e the syn-
thesis and secretion of FGF21 by these tissues into the circulation
may change concomitant to age-related alterations in body
composition.
In humans, serum FGF21 concentrations appear to vary between
individuals and across age groups, but to-date there is no single
dataset across age groups. In separate studies, higher circulating
values have been reported in adults compared to children, but an
underlying explanation has not been elucidated. Further, values
have been reported to vary widely (e.g., 250-fold) among healthy
normal-weight adults ages 20e80 y, ranging from 21 to 5300 pg/ml
[10]. While less studied in children, a recent investigation in a
healthy, non-obese pediatric Danish cohort, including subjects ages
8e16 y, reported a range from below level of detection (30 pg/ml) to
1715.1 pg/ml [11]. To our knowledge no studies have examined
FGF21 across age groups in healthy individuals. Thus, the two-fold
objective of this study was to assess fasting FGF21 concentrations
across age groups, ranging from 5 to 70 y, and to assess whether




Fasting blood samples were obtained from the compilation of
several pediatric and two adult studies conducted at University ofAlabama at Birmingham (UAB). Speciﬁc study inclusion criteria
have been published elsewhere for pediatric [12e15] and adult
cohorts [16,17]. While the cited studies include interventional
components, the current investigation is limited to cross-sectional
analyses of baseline data for all participants. For each of these
studies, subjects were recruited using newspaper advertisements,
posted ﬂyers, by word-of-mouth and through local radio adver-
tisements. All measurements were performed at the Clinical
Research Unit (CRU), UAB Center for Exercise Medicine and the
Human Physiology Core at UAB. All study protocols were approved
by the Institutional Review Boards (IRBs) of UAB and/or the Bir-
minghamVeterans Affairs Medical Center, and all subjects provided
written, informed consent and assent (where appropriate) prior to
participation to utilize samples collected for future research.
Children/adolescents
The pediatric population included participants enrolled in a
variety of clinical studies conducted at UAB investigating metabolic
changes during growth and maturation [12e15]. The total pediatric
sample included 69 healthy children ages 5e12 y (Tanner
stage < 4), who underwent DXA scans and fasting morning veni-
puncture over the period of 2009e2014. Exclusionary criteria for
each of the studies were medical diagnoses and/or current use of
medications known to affect body composition, lipid or glucose
metabolism, or blood pressure (e.g., diabetes; impaired fasting
glucose; use of thyroid medication, diuretics, beta-blockers, thia-
zolidinediones, etc.); an allergy to lidocaine (used for topical
anesthesia prior to venipuncture in study participants); and history
of an eating disorder(s). The study physician conducted an overall
health assessment for each of the participants to rule out medical
diagnoses.
Adults
The de-identiﬁed data and samples from adults 20e80þ yr
derived from fasting morning venipuncture encompassing the
baseline assessments in one of two studies [16,17]. For each of these
studies, subjects were free of any musculoskeletal or other disor-
ders that could potentially affect their ability to complete testing.
Subjects were non-obese (BMI < 30) and none of the participants
were treated with pharmacological interventions thought to in-
ﬂuence body composition or glucose metabolism.Body composition and fat distribution
Body composition indices [percent lean mass, bone mineral
density (BMD), total percent fat mass, and percent trunk fat] were
determined using dual energy x-ray absorptiometry (DXA) scans
(GE Lunar Corporation, Madison, WI, USA) and encore 2002 soft-
ware (version 6.10.029) according to manufacturer’s instructions
(pediatric version where appropriate). Subjects were scanned in
light clothing, lying ﬂat on their back with arms at their sides.Serum assay
For all participants, blood was drawn in the morning after an
overnight fast. Serum concentrations of FGF21 were measured
using a commercially-available, enzyme-linked immunosorbent
assay (ELISA; Millipore Corporation, Billerica, MA). All samples
were processed immediately upon completion of blood draw to
extract serum samples and subsequently stored at 80 until
measurement of the analytes of interest in batched assays in
accordance with assay speciﬁcations. The inter-assay coefﬁcient of
variation (CV) was <11% and intra-assay CV was <5%. The mini-
mum sensitivity was 31.3 pg/ml. Four participants (all children)
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set to 29 pg/ml.
Data analysis
Descriptive statistics (mean  standard deviation) were deter-
mined to describe age- and FGF21 tertile-speciﬁc categories. FGF21
was not normally distributed, thus median and interquartile ranges
were reported. Natural log transformation was used FGF21 to ach-
ieve normal distribution for and was subsequently used in this form
for analyses. General linear models were used to analyze differ-
ences in parameters by age as a categorical variable and FGF21
tertile with Tukey’s test to evaluate post hoc group-wise differences,
all controlled for sex [except for when determining differences in
age, sex and BMI percentile (sex-speciﬁc) by FGF21 tertile]. In
addition to sex, weight was also adjusted for when evaluating dif-
ferences in weight by age category and FGF21 tertile.
Partial Pearson correlations were analyzed using log-
transformed FGF21 and absolute body composition indices (i.e.,
percent lean mass, BMD, percent fat mass, and percent trunk fat)
controlling for sex. Multiple linear regression analyses were per-
formed in the overall sample and by FGF21 tertile, with log FGF21 as
the dependent variable and the categorical variable, age group, as
the independent variable. All models were controlled for sex, with
individual addition of body composition indices to models. Statis-
tical signiﬁcance was accepted at P  0.05 for all tests using SAS
software (version 9.4, SAS Institute Inc., Cary NC).
Results
Participant characteristics
Participant (n ¼ 184; 45% male) descriptive characteristics are
presented by age category as follows: children, 5e12 y; young
adults, 20e29 y; adults, 30e50 y; older adults, 55e64 y; elder
adults, 65e80 y (Table 1). Adults were all non-obese (BMI <30 kg/
m2), while 44.9% of the children were obese based on CDC sex- and
age-speciﬁc criteria (95th BMI percentile) [18]. FGF21 levels
increased as age group increased (lower in children relative to
adults, older adults and elder adults, and lower in young adults and
adults relative to elder adults all P < 0.01). Sex-adjusted body
composition variable comparisons revealed no differences in BMD
among adult categories but greater BMD in all adult groups relative
to children (P  0.05). Percent total fat and percent lean mass were
highest and lowest, respectively, in elder adults (P  0.05)
compared to all except older adults. Percent trunk fat was highest in
elder adults and older adults (P  0.05), who did not differ from
each other.Table 1
Descriptive statistics [mean  SD or median (interquartile range)] categorized by age gr
Children,d n ¼ 69
(5e12 y, 38% male)
Young adults, n ¼ 21
(20e29 y, 48% male)
Height (cm) 139.5 ± 12.4 167.6  8.1
Weight (kg)e 44.1 ± 17.0 67.3  11.7a
BMI 75.7th ± 29.8f 23.8  3.0a
FGF21 (median, IQR) 156.0 (59.0, 254.0)a 211.0 (140.0, 302.0)a,b
FGF21 (minemax) 29.0e595.0 34.0e615.0
Total lean (%) 63.3  9.2a 67.0  9.9a
BMD (g/cm3) 0.9  0.1a 1.2  0.1b
Total fat (%) 32.6  9.7a 29.4  10.7a
Trunk fat (%) 13.4  6.1a 12.9  4.8a
Fibroblast growth factor 21 (FGF21), bone mineral density (BMD).
a,b,crepresents age group differences (all adjusted for sex, dTanner 1 (51%), Tanner 2 (33
variables in bold are not compared with adults; fBMI percentile.Table 2 presents sample characteristics by FGF21 tertile. There
were age, height, weight, BMD, and percentage trunk fat differences
when analyzed by tertile of FGF21. Mean age signiﬁcantly increased
across ascending tertiles of FGF21. Height, weight and BMD were
greatest in the highest FGF21 tertile relative to the lowest tertile,
and percent trunk fat was greatest in the highest FGF21 tertile
relative to lowest and mid-tertiles (all P  0.05). There were no sex
differences by FGF21 tertile, nor were there differences in BMI, BMI
percentile, lean mass percent or total fat mass percent.
Partial Pearson correlations between log FGF21 and body
composition indices
FGF21 was correlated positively with percent trunk fat (r ¼ 0.25,
P ¼ 0.001) and BMD (r ¼ 0.30, P < 0.0001), but not with percent
total fat (r ¼ 0.10, P ¼ 0.187) or percent lean mass (r ¼ 0.07,
P ¼ 0.339).
Multivariable associations
Table 3 presents multiple linear regression analyses in the
overall sample and by tertile of FGF21, with age group as the in-
dependent variable, and FGF21 as the dependent variable (con-
trolling for sex). FGF21 was positively associated with age group
(categorical variable) independent of individual body composition
indices (parameter estimate/b for age group including the following
covariates in individual models: percent lean mass, b ¼ 0.25; BMD,
b ¼ 0.24; percent total fat mass, b ¼ 0.24; percent trunk fat,
b ¼ 0.23; all P< 0.0001). By FGF21 tertile, age group was associated
with log FGF21 in the lowest tertile only (parameter estimate/b for
age group including the following covariates in individual models:
percent lean mass, b ¼ 13.1; percent total fat mass, b ¼ 0.19; and
percent trunk fat, b ¼ 0.18; all P  0.01), but not when accounting
for BMD.
Discussion
Prior investigations of FGF21 have focused on its ability to
improve glucose regulation and lipid handling in disordered
metabolic states (e.g., obesity, T2DM, cardiovascular disease). While
a regulatory role in various metabolic functions has become
apparent, the targeted actions of FGF21 in humans are likely
inﬂuenced by changing metabolic demands over the life course. We
found an increase in circulating FGF21 levels with age in healthy
individuals independent of body composition indices. When
examined across FGF21 tertiles, older age category was associated
with greater concentrations of FGF21 in the lowest tertile only,
independent from measures of lean and fat mass, but not whenoup
Adults, n ¼ 27
(30e50 y, 44% male)
Older adults, n ¼ 31
(55e64 y, 48% male)
Elder adults, n ¼ 36
(65e80 y, 58% male)
173.3  10.4 171.4  10.2 170.1  11.2
75.5  11.7a,b 74.5  14.0a,b 78.1  14.6b
25.1  2.2a 25.2  3.1a 26.8  2.9b
267.0 (156.0, 411.0)b,c 292.0 (177.0, 499.0)b,c 358.5 (238.5, 481.0)c
47.0e666.0 55.0e766.0 129.0e822.0
64.9  8.2a,b 63.2  6.7a,b 59.0  6.7b
1.2  0.1b 1.2  0.1b 1.2  0.1b
31.6  8.2a,b 33.0  7.1a,b 37.5  6.1b
15.0  3.4a,b 17.0  3.9b,c 19.2  3.3c
%), Tanner 3 (10%), Tanner 4 (6%); evariable also adjusted for height; all P  0.05);
Table 2
Sample characteristics [mean  SD or median (interquartile range)] by FGF21 tertile
Tertile 1, n ¼ 60 Tertile 2, n ¼ 63 Tertile 3 (n ¼ 61)
Age 23.3  20.5a 36.9  24.5b 49.4  23.8c
% Male 41.7 46.0 45.9
Heightc 152.6  17.3a 159.9  20.2a,b 164.6  17.0b
Weightd 56.2  19.9a 63.1  22.6a,b 70.1  18.4b
BMIc,e 24.6  3.3 25.3  3.0 25.9  2.8
BMI percentilee 78.5  28.7 68.7  32.1 80.4  28.6
Total lean (%)c 63.3  9.5 64.3  8.0 61.6  7.9
BMD (g/cm3)c 1.0  0.2a 1.1  0.2a,b 1.1  0.2b
Total fat (%)c 32.5  10.2 32.2  8.4 34.8  7.8
Total trunk fat (%)c 14.0  5.7a 14.8  5.4a 17.2  4.2b
Fibroblast growth factor 21 (FGF21), bone mineral density (BMD).
a,brepresents differences by FGF21 tertile (P  0.05), cadjusted for sex, dadjusted for
height and sex, eBMI includes adults only, where BMI percentile includes only
children.
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regarding a potential differential role of FGF21 during anabolic (as
with childhood growth) versus catabolic states (as with aging) at
variable physiological levels. The considerable inter-individual
variability of circulating FGF21 level in humans as they age may
reside in temporal changes in tissue distribution and responsive-
ness to metabolic demand.
Although longitudinal studies in humans have not been con-
ducted, cross-sectional median serum FGF21 values reported
among adult populations have been typically higher relative to
pediatric populations. In our sample, characterized by healthy in-
dividuals across a wide spectrum of ages, FGF21 levels were like-
wise lowest among children/adolescents. We report concentrations
within a more narrow range than that previously reported e from
below level of detection (31.3 pg/ml) to 595 in healthy boys and
girls of varied body habitus (normal weight, overweight and obese)
whose mean agewas 9.5 y 1.8 [11], with a similar median value of
156 pg/ml (59, 254). Based on an in vitro study of primary human
chondrocytes, FGF21 may inhibit linear growth by induction of
growth hormone resistance [19]. Given our lack of information on
individual growth velocities, we were unable to correlate this with
serum FGF21. We posit that the balance of anabolic and catabolic
processes supporting growth and tissue maintenance may underlie
the difference in adults and children.
We further examined FGF21 levels after excluding children and
found a fairly wide range of absolute FGF21 levels (34e822 pg/ml).Table 3
Association between FGF21 (dependent variable) and age groupa (independent
variable), controlling for body composition indices in individual models in the












n 184 61 62 61
Variable b
Age group 0.25a 13.1b 0.73 4.49
% lean mass 7.8  104 0.13 0.38 1.94
Age group 0.24a 0.12 0.01 0.01
BMD 0.09 0.72 0.17 0.04
Age group 0.24a 0.19b 1.6  103 0.01
% fat mass 1.6  103 1.7  103 1.8  103 3.7  103
Age group 0.23a 0.18b 8.6  104 0.02
% trunk fat 0.01 0.01 6.2  104 0.1
Bone mineral density (BMD). Bolded values indicate signiﬁcant associations
(aP < 0.0001; bP  0.01).
a Children, 5e12 y; young adults, 20e29 y; adults, 30e50 y; older adults, 55e64;
elder adults, 65e80.Median values in young adults were 211 pg/ml, adults 267 pg/ml,
older adults 292 pg/ml, and elder adults 359 pg/ml, values similar to
some but not all reports. Elder adults had the greatest FGF21 levels,
ranging from 129 to 822 pg/ml. A study of healthy adults similar in
age to our cohort of older adults (n ¼ 50, mean age 65.3 y) found a
fasting serum FGF21 concentration of 468 pg/ml (295, 520) [20], yet
another study (n ¼ 539, mean age 61.9 y) reported a value two-fold
lower of 210 pg/ml (114, 335) [21]. Notably, both studies had similar
demographic characteristics (e.g., sex, BMI) as ours. Although the
adults in comparative studies were presumed healthy based on
their identiﬁcation as “controls,” a potential inﬂuence of metabolic
health (i.e., presence of morbidities) could explain the discordant
values. The cohort with higher values included a small percentage
of participants with clinical characteristics indicative of metabolic
derangement known to be associated with elevated FGF21 con-
centrations (e.g., hypertension, cardiovascular events, cancer,
osteoarthritis, chronic kidney disease) [8,22,23]. In both reference
cohorts, relative to controls, circulating FGF21 was greater among
individuals with impairments in glucose regulation (individuals
with overt T2DM and indication of pre-diabetes), which has also
been found in other studies [2,8,24]. Another recent study reported
a mean concentration of FGF21 of 254 pg/ml  113, with a range
from 17 to 629 pg/ml [25] in men (n ¼ 160; 30e79 y; mean BMI
24.1 kg/m2) with no history of chronic diseases, Of note, in that
study two outliers displaying extremely high concentrations of
FGF21were excluded from the analysis (1914 and 2411 pg/ml). In-
clusion of the outliers would have markedly increased the reported
mean value. Also noteworthy, ELISA assay kits differed across
studies (Jian: BioVendor Laboratory Medicine, Modrice, Czech Re-
public; Semba and Taniguchi: R&D Systems, Minneapolis, MN;
Hanks: Millipore Corporation, Billerica, MA), which may certainly
contribute to reported discrepancies. As interest continues to
generate regarding the role of FGF21 and metabolic health out-
comes, particularly in context of dynamic periods of growth, further
evaluation into physiologically ‘normal’ levels is warranted.
Due to differences in metabolic activity, body composition
compartments vary in energy requirements [26]. The dynamic
interaction between tissue partitioning and bioenergetics due to
metabolic demand over the life course may contribute to differ-
ences in FGF21 with age. The characteristic amassment of body fat
and reduction in fat-free mass in adulthood differs from tissue
partitioning in childhood when increased metabolic demand leads
to gains in both fat and fat-free mass. As might be anticipated with
changes in tissue compartments, percent total fat and trunk fat
increased with increasing age categories, whereas mean BMD
remained stable across adult categories (albeit expectedly higher
relative to children). Lean mass was numerically highest among
young adults, which was a signiﬁcantly higher value relative to
elder adults. To assess whether the observed differences in body
composition may contribute to the association between FGF21 and
age group, the inﬂuence of the various indices of body composition
was assessed. The age category variable remained a signiﬁcant
predictor of FGF21 levels in statistical models independent of each
body composition parameter. This suggests that, among healthy
individuals, quantitative differences in fat and fat-free mass do not
inﬂuence age-related levels of circulating FGF21.
Because we hypothesized FGF21 levels in circulation may be in
response tometabolic demand, we also evaluatedwhether age and/
or body composition may differentially inﬂuence FGF21 level at
lower, middle or relatively high concentrations of FGF21. By tertile
of FGF21, age group explained the variance in FGF21 concentration
in only the lowest tertile independently of percent lean, total fat,
and trunk fat, but not BMD. While not apparent in overall models,
this ﬁnding suggests that the metabolically active, energy
demanding skeleton may exert greater inﬂuence on metabolic
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At lower tertiles of FGF21, age, BMD and trunk fat were lower
relative to higher tertiles. FGF21 synthesis and release may be a
compensatory response to (re)establish metabolic control.
Not only does body composition undergo changes with age, so
too does a multitude of hormones and factors involved in growth,
maturation, and maintenance of systemic physiologic re-
quirements. PPARs, which inﬂuence the contribution by the liver
and adipose tissue to FGF21 appearance in circulation, are key
regulators in various age-associated pathophysiological processes
related to energy metabolism and oxidative stress [27]. PPARs are
also associated with bone resorptive (catabolic) processes [28,29].
In addition, several studies have demonstrated that PPARa and
PPARg inhibit the expression of inﬂammatory genes, such as cyto-
kines, metalloproteases, and acute phase proteins [30]. In future
studies, the governance of FGF21 expression and secretion by
speciﬁc hormones and transcription factors warrant consideration.
Age may have more of an inﬂuence on FGF21 levels in youngest
individuals, which could be explained by differential underlying
regulatory factors and pathways which also undergo aged-related
differences. Whether maintenance of bone mass in individuals
with lower physiologic FGF21 levels may attenuate FGF21 secretion
into the circulation warrants further investigation.
Our study had several notable strengths. Our cohort included a
wide age range (i.e., childhood through late adulthood) and the
method used to assess body composition (DXA) is notably robust.
Despite the strengths of this study, there were some limitations.
Although participants were considered to be overall healthy, spe-
ciﬁc measures of glucose, insulin and lipid homeostasis would have
provided further insight. While the adult cohort included only non-
obese individuals, the pediatric population included a wider range
of body habitus based on BMI centiles. The inclusion of body
composition parameters analyzed by the sophisticated technique,
DXA, limited this potential for confounding. This study was cross-
sectional in nature, which disallowed the ability to assess longitu-
dinal changes.
In conclusion, our ﬁndings in a healthy population display an
age-related increase in circulating FGF21, highlighting a potential
differential age effect in response to metabolic demand over the
lifecourse. At lower levels of FGF21, however, bone density may
explain the age-related association. Given the role of FGF21 in
cellular energy metabolism as a regulator of lipid and glucose uti-
lization in animal models and our ﬁndings presented herein, at this
stage it is unclear whether the age-related increases of FGF21 are a
consequence of body composition or, alternatively, causative.Conﬂicts of interest
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